

A2  
Cost  
asthma, general food allergies, ulcerative colitis, atopic  
eczema, chronic urticaria, and irritable bowel syndrome if  
it is presented such that the respective chromone becomes  
bioavailable within ten minutes of exposure to an  
intestinal fluid.

#### In the Claims

Please withdraw Claims 10-15 and 17-29 from present  
consideration, but with right of reintroduction being  
maintained.

Please amend Claims 6, 8, and 16 as follows.

A3  
6. A composition according to any<sup>one</sup> of the preceding  
claims wherein the composition further comprises  
disintegrant at a ratio of at least 1.4:1(w:w) of  
disintegrant to chromone.

A4  
8. An oral drug delivery composition comprising a  
chromone wherein the composition further comprises  
disintegrant at a ratio of at least 1.4:1 (w:w) of  
disintegrant to chromone.

A5  
16. A composition according to any one of claims 6,  
8, or 9 wherein the disintegrant is microcrystalline  
cellulose.

Please add new claims 30-33 as follows.

A6  
30. A composition according to any<sup>one</sup> of the preceding  
claims further comprising an amphoteric surfactant or a

surfactant having a hydrophile-lipophile balance (HLB) value of less than about 10.

As  
cost  
31. A composition according to claim 7 or (10) wherein the pellets are melt pellets.

32. A composition according to any one of claims 7 or 31 wherein the pellets have a diameter of between 0.7mm and 1.8mm.

33. A composition according to any one of the preceding claims wherein the chromone is sodium cromoglycate.

---

Remarks

Applicant acknowledges Examiner's restriction requirement to Claims 1-9 and 16, and hereby withdraws pending claims 10-15 and 17-29 from present consideration. However, Applicant respectfully maintains the right to reinsert such non-elected claims at a later time.

As kindly pointed out by the Examiner, Applicant wishes to insert an abstract as required by 37 CFR §1.72(b). The abstract provided herein does not introduce new matter into the disclosure, and should therefore be incorporated into the application.

Claims 10-15 and 17-29 have been withdrawn from present consideration. Claims 6, 8, and 16 have been amended. New claims 30-33 have been added. Claims 1-9,